Discovery of MK-6169, a Potent Pan-Genotype Hepatitis C Virus NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Substitutions.

doi:10.1021/acs.jmedchem.7b01927

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Discovery of MK-6169, a Potent Pan-Genotype Hepatitis C Virus NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Substitutions.

Journal of medicinal chemistry - 10 May 2018

Yu Wensheng, Tong Ling, Selyutin Oleg, Chen Lei, Hu Bin, Zhong Bin, Hao Jinglai, Ji Tao, Zan Shuai, Yin Jingjun, Ruck Rebecca T, Curry Stephanie, McMonagle Patricia, Agrawal Sony, Rokosz Laura, Carr Donna, Ingravallo Paul, Bystol Karin, Lahser Frederick, Liu Rong, Chen Shiying, Feng Kung-I, Cartwright Mark, Asante-Appiah Ernest, Kozlowski Joseph A

Abstract excerpt

We describe the discovery of MK-6169, a potent and pan-genotype hepatitis C virus NS5A inhibitor with optimized activity against common resistance-associated substitutions. SAR studies around the combination of changes to both the valine and aminal carbon region of elbasvir led to the discovery of a series of compounds with substantially improved potency against common resistance-associated substitutions in the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dogs

Share to Drug Discovery

Share to Drug Resistance, Viral

Share to Hepacivirus

Share to Rats

Share to Tissue Distribution

Share to Viral Nonstructural Proteins

Source

Open in PubMed

Identifiers

PMID: 29681153
DOI: 10.1021/acs.jmedchem.7b01927

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discovery of MK-6169, a Potent Pan-Genotype Hepatitis C Virus NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Substitutions.PMID 29681153Read ↗

GSK2818713, a Novel Biphenylene Scaffold-Based Hepatitis C NS5A Replication Complex Inhibitor with Broad Genotype Coverage.Semantic proximity Read ↗

Molecular and Structural Mechanism of Pan-Genotypic HCV NS3/4A Protease Inhibition by Glecaprevir.Semantic proximity Read ↗

Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A.Semantic proximity Read ↗

MK-8325: A silyl proline-containing NS5A inhibitor with pan-genotype activity for treatment of HCV.Semantic proximity Read ↗

Discovery of silyl proline containing HCV NS5A inhibitors with pan-genotype activity: SAR development.Semantic proximity Read ↗

Molecular mechanism by which a potent hepatitis C virus NS3-NS4A protease inhibitor overcomes emergence of resistance.Semantic proximity Read ↗

Discovery of fused tricyclic core containing HCV NS5A inhibitors with pan-genotype activity.Semantic proximity Read ↗

Discovery of ravidasvir (PPI-668) as a potent pan-genotypic HCV NS5A inhibitor.Semantic proximity Read ↗

Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymerase.Semantic proximity Read ↗

Discovery of daclatasvir, a pan-genotypic hepatitis C virus NS5A replication complex inhibitor with potent clinical effect.Semantic proximity Read ↗

Discovery of a Silicon-Containing Pan-Genotype Hepatitis C Virus NS5A Inhibitor.Semantic proximity Read ↗

Novel Pan-Coronavirus 3CL Protease Inhibitor MK-7845: Bio-Logical and Pharmacological ProfilingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.